Asaf Vivante1,2, Orna Staretz Chacham3, Shirlee Shril1, Ruth Schreiber4, Shrikant M Mane5, Ben Pode-Shakked2,6, Neveen A Soliman7, Irene Koneth8, Mario Schiffer9, Yair Anikster6, Friedhelm Hildebrandt10. 1. Division of Nephrology, Department of Medicine, Boston Children's Hospital, Harvard Medical School, 300 Longwood Avenue, Boston, MA, USA. 2. Department of Pediatrics B and Pediatric Nephrology unit, Talpiot Medical Leadership Program, Sheba Medical Center, Tel-Hashomer and Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel. 3. Metabolic Clinic, Pediatric Division, Soroka University Medical Center, Ben-Gurion University, Beer Sheva, Israel. 4. Faculty of Health Sciences, Pediatric Nephrology Clinic, Pediatric Division, Soroka University Medical Center, Ben-Gurion University, 84101, Beer Sheva, Israel. 5. Department of Genetics, Yale University School of Medicine, New Haven, CT, 06510, USA. 6. Metabolic Disease Unit, Edmond and Lily Safra Children's Hospital, Sheba Medical Center, Tel-Hashomer and Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel. 7. Department of Pediatrics, Kasr Al Ainy School of Medicine, Cairo, Egypt and Egyptian Group for Orphan Renal Diseases (EGORD), Cairo University, Cairo, Egypt. 8. Department of Nephrology and Transplantation Medicine, Kantonsspital St. Gallen, St. Gallen, Switzerland. 9. Clinic for Nephrology and Hypertension Ulmenweg 18, 91054, Erlangen, Germany. 10. Division of Nephrology, Department of Medicine, Boston Children's Hospital, Harvard Medical School, 300 Longwood Avenue, Boston, MA, USA. friedhelm.hildebrandt@childrens.harvard.edu.
Abstract
BACKGROUND: Heterozygous PAX2 mutations cause renal coloboma syndrome (RCS) [OMIM no. 120330]. RCS is a renal syndromic disease encompassing retinal coloboma and sensorineural hearing loss. Recently, a causative role for PAX2 was reported in adult-onset nephrotic syndrome secondary to focal segmental glomerulosclerosis (FSGS). However, the prevalence of PAX2 mutations among large cohort of children with steroid-resistant nephrotic syndrome (SRNS) and FSGS has not been systematically studied. METHODS: We employed whole-exome sequencing (WES) to identify the percentage of SRNS cases explained by monogenic mutations in known genes of SRNS/FSGS. As PAX2 mutations are not an established cause of childhood FSGS, we evaluated a cohort of 215 unrelated families with SRNS, in whom no underlying genetic etiology had been previously established. RESULTS: Using WES, we identified 3 novel causative heterozygous PAX2 mutations in 3 out of the 215 unrelated index cases studied (1.3%). All three cases were detected in individuals from families with more than one affected and compatible with an autosomal dominant mode of inheritance (3/57 familial cases studied (5.2%)). The clinical diagnosis in three out of four pediatric index patients was done during routine medical evaluation. CONCLUSIONS: Our findings demonstrate high frequency of PAX2 mutations in familial form of SRNS (5.2%) and further expand the phenotypic spectrum of PAX2 heterozygous mutations to include autosomal dominant childhood-onset FSGS. These results highlight the importance of including PAX2 in the list of genes known to cause FSGS in children.
BACKGROUND: Heterozygous PAX2 mutations cause renal coloboma syndrome (RCS) [OMIM no. 120330]. RCS is a renal syndromic disease encompassing retinal coloboma and sensorineural hearing loss. Recently, a causative role for PAX2 was reported in adult-onset nephrotic syndrome secondary to focal segmental glomerulosclerosis (FSGS). However, the prevalence of PAX2 mutations among large cohort of children with steroid-resistant nephrotic syndrome (SRNS) and FSGS has not been systematically studied. METHODS: We employed whole-exome sequencing (WES) to identify the percentage of SRNS cases explained by monogenic mutations in known genes of SRNS/FSGS. As PAX2 mutations are not an established cause of childhood FSGS, we evaluated a cohort of 215 unrelated families with SRNS, in whom no underlying genetic etiology had been previously established. RESULTS: Using WES, we identified 3 novel causative heterozygous PAX2 mutations in 3 out of the 215 unrelated index cases studied (1.3%). All three cases were detected in individuals from families with more than one affected and compatible with an autosomal dominant mode of inheritance (3/57 familial cases studied (5.2%)). The clinical diagnosis in three out of four pediatric index patients was done during routine medical evaluation. CONCLUSIONS: Our findings demonstrate high frequency of PAX2 mutations in familial form of SRNS (5.2%) and further expand the phenotypic spectrum of PAX2 heterozygous mutations to include autosomal dominant childhood-onset FSGS. These results highlight the importance of including PAX2 in the list of genes known to cause FSGS in children.
Entities:
Keywords:
Congenital anomalies of the kidneys and urinary tract (CAKUT); FSGS; SRNS and PAX2
Authors: J Amiel; S Audollent; D Joly; P Dureau; R Salomon; A L Tellier; J Augé; F Bouissou; C Antignac; M C Gubler; M R Eccles; A Munnich; M Vekemans; S Lyonnet; T Attié-Bitach Journal: Eur J Hum Genet Date: 2000-11 Impact factor: 4.246
Authors: Moumita Barua; Emilia Stellacci; Lorenzo Stella; Astrid Weins; Giulio Genovese; Valentina Muto; Viviana Caputo; Hakan R Toka; Victoria T Charoonratana; Marco Tartaglia; Martin R Pollak Journal: J Am Soc Nephrol Date: 2014-03-27 Impact factor: 10.121
Authors: Jillian K Warejko; Weizhen Tan; Ankana Daga; David Schapiro; Jennifer A Lawson; Shirlee Shril; Svjetlana Lovric; Shazia Ashraf; Jia Rao; Tobias Hermle; Tilman Jobst-Schwan; Eugen Widmeier; Amar J Majmundar; Ronen Schneider; Heon Yung Gee; J Magdalena Schmidt; Asaf Vivante; Amelie T van der Ven; Hadas Ityel; Jing Chen; Carolin E Sadowski; Stefan Kohl; Werner L Pabst; Makiko Nakayama; Michael J G Somers; Nancy M Rodig; Ghaleb Daouk; Michelle Baum; Deborah R Stein; Michael A Ferguson; Avram Z Traum; Neveen A Soliman; Jameela A Kari; Sherif El Desoky; Hanan Fathy; Martin Zenker; Sevcan A Bakkaloglu; Dominik Müller; Aytul Noyan; Fatih Ozaltin; Melissa A Cadnapaphornchai; Seema Hashmi; Jeffrey Hopcian; Jeffrey B Kopp; Nadine Benador; Detlef Bockenhauer; Radovan Bogdanovic; Nataša Stajić; Gil Chernin; Robert Ettenger; Henry Fehrenbach; Markus Kemper; Reyner Loza Munarriz; Ludmila Podracka; Rainer Büscher; Erkin Serdaroglu; Velibor Tasic; Shrikant Mane; Richard P Lifton; Daniela A Braun; Friedhelm Hildebrandt Journal: Clin J Am Soc Nephrol Date: 2017-11-10 Impact factor: 8.237
Authors: J Favor; R Sandulache; A Neuhäuser-Klaus; W Pretsch; B Chatterjee; E Senft; W Wurst; V Blanquet; P Grimes; R Spörle; K Schughart Journal: Proc Natl Acad Sci U S A Date: 1996-11-26 Impact factor: 11.205
Authors: Carolin E Sadowski; Svjetlana Lovric; Shazia Ashraf; Werner L Pabst; Heon Yung Gee; Stefan Kohl; Susanne Engelmann; Virginia Vega-Warner; Humphrey Fang; Jan Halbritter; Michael J Somers; Weizhen Tan; Shirlee Shril; Inès Fessi; Richard P Lifton; Detlef Bockenhauer; Sherif El-Desoky; Jameela A Kari; Martin Zenker; Markus J Kemper; Dominik Mueller; Hanan M Fathy; Neveen A Soliman; Friedhelm Hildebrandt Journal: J Am Soc Nephrol Date: 2014-10-27 Impact factor: 10.121
Authors: Nina Mann; Slim Mzoughi; Ronen Schneider; Susanne J Kühl; Denny Schanze; Verena Klämbt; Svjetlana Lovric; Youying Mao; Shasha Shi; Weizhen Tan; Michael Kühl; Ana C Onuchic-Whitford; Ernestine Treimer; Thomas M Kitzler; Franziska Kause; Sven Schumann; Makiko Nakayama; Florian Buerger; Shirlee Shril; Amelie T van der Ven; Amar J Majmundar; Kristina Marie Holton; Amy Kolb; Daniela A Braun; Jia Rao; Tilman Jobst-Schwan; Eva Mildenberger; Thomas Lennert; Alma Kuechler; Dagmar Wieczorek; Oliver Gross; Beate Ermisch-Omran; Anja Werberger; Martin Skalej; Andreas R Janecke; Neveen A Soliman; Shrikant M Mane; Richard P Lifton; Jan Kadlec; Ernesto Guccione; Michael J Schmeisser; Martin Zenker; Friedhelm Hildebrandt Journal: J Am Soc Nephrol Date: 2021-02-16 Impact factor: 10.121
Authors: Anthony J Bleyer; Maggie Westemeyer; Jing Xie; Michelle S Bloom; Katya Brossart; Jason J Eckel; Frederick Jones; Miklos Z Molnar; Wayne Kotzker; Prince Anand; Stanislav Kmoch; Yuan Xue; Samuel Strom; Sumit Punj; Zachary P Demko; Hossein Tabriziani; Paul R Billings; Trudy McKanna Journal: Am J Nephrol Date: 2022-03-24 Impact factor: 4.605